Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Hashim Abbas, Lisa A. Rybicki, MS, Frederic J. Reu, MD, Christy Samaras, DO, Mitchell R. Smith, Debbie Hastings, Jason Valent, MD

Blood (2016) 128 (22): 5813.

https://doi.org/10.1182/blood.V128.22.5813.5813

Published: 2016

Journal Articles

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Frederic J. Reu, MD, Jason Valent, MD, Ehsan Malek, MD, Ronald M. Sobecks, MD, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Jamie Elberson, RN, Sherry Fada, Hien K. Liu, MD, Christy Samaras, DO, Mitchell R. Smith, MD PhD

Blood (2015) 126 (23): 4221.

https://doi.org/10.1182/blood.V126.23.4221.4221

Published: 2015

Journal Articles

Response Adapted Induction Therapy for Multiple Myeloma

Jason Valent, MD, Christy Samaras, DO, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Brian J. Bolwell, MD, Janice Reed, RN, Mary Ann Karam, RN, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Mitchell R. Smith, MD PhD, Hien K. Liu, MD, Frederic J Reu

Blood (2015) 126 (23): 3327.

https://doi.org/10.1182/blood.V126.23.3327.3327

Published: 2015

Journal Articles

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Mayur Narkhede, MD, Jason Valent, MD, Chad Cummings, MBA, Katherine Glass, MPH, MS, Debbie Hastings, Beth Faiman, PhD, CNP, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt E. Kalaycio, MD, Brian J. Bolwell, MD, Mitchell R. Smith, MD PhD, Hien K. Duong, MD, Christy Samaras, DO, Frederic J. Reu, MD

Blood (2014) 124 (21): 2620.

https://doi.org/10.1182/blood.V124.21.2620.2620

Published: 2014

Journal Articles

Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis

Naresh Bumma, MD, Frederic J. Reu, MD, Christy Samaras, DO, Hien K. Duong, MD, Mitchell R. Smith, MD PhD, Jason Valent, MD

Blood (2014) 124 (21): 4753.

https://doi.org/10.1182/blood.V124.21.4753.4753

Published: 2014

Journal Articles

Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis

Surbhi Sidana, MD, Beth Faiman, PhDc, CNP, Paul Elson, ScD, Mitchell R Smith, MD, PhD, Robert M Dean, MD, Jason Valent, M.D., Christy Samaras, DO, Hien K. Duong, MD, Debbie Hastings, Kellie Bruening, Frederic J. Reu, MD

Blood (2013) 122 (21): 1975.

https://doi.org/10.1182/blood.V122.21.1975.1975

Published: 2013

Journal Articles

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

Alan P. Z. Skarbnik, MD, Craig A. Portell, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD, Brad Pohlman, MD, Manuel G. Afable, II, Anjali S. Advani, MD, Robert M Dean, MD, Brian T. Hill, MD, PhD, Leonard J. Horwitz, MD, Deepa Jagadeesh, MD, MPH, Alan E. Lichtin, Christy Samaras, DO, Mikkael A. Sekeres, MD, MS, Michael Millenson, MD, Mitchell R Smith, MD, PhD

Blood (2013) 122 (21): 1387.

https://doi.org/10.1182/blood.V122.21.1387.1387

Published: 2013

Journal Articles

Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma

Beth Faiman, PhDc, CNP, Surbhi Sidana, MD, Paul Elson, ScD, Kellie Bruening, Hien K. Duong, MD, Robert M Dean, MD, Jason Valent, M.D., Christy Samaras, DO, Debbie Hastings, Mitchell R Smith, MD, PhD, Frederic J. Reu, MD

Blood (2013) 122 (21): 5397.

https://doi.org/10.1182/blood.V122.21.5397.5397

Published: 2013

Journal Articles

Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study

Frederic J. Reu, MD, Shahper N Khan, PhD, Reda Z Mahfouz, MD/PhD, Robert M Dean, MD, Beth Faiman, CNP, Janice Reed, RN, Mary Ann Karam, RN, Kimberly Hamilton, RN, Sherry Fada, Matt Kalaycio, MD, Erica L. Campagnaro, MD, Tamila L. Kindwall-Keller, DO, Jason Valent, M.D., Christy Samaras, DO, Ronald Sobecks, MD, Carolyn Jirousek, R. N., Hien K. Duong, MD, Mohammed Orloff, Ph.D., Yogen Saunthararajah, MD

Blood (2012) 120 (21): 5031.

https://doi.org/10.1182/blood.V120.21.5031.5031

Published: 2012

NARROW

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Response-Adapted Therapy for Newly Diagnosed Myeloma

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Response Adapted Induction Therapy for Multiple Myeloma

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis

Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma

Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only